Employer Active
Job Alert
You will be updated with latest job alerts via emailJob Alert
You will be updated with latest job alerts via emailA postdoctoral fellowship in the field of cancer immunotherapy to work on Safety-Enhanced Chimeric Antigen Receptors (SECAR) will be available for a period of 30 months starting from November 2025. This postdoctoral fellowship is funded by Helse Sr -st.
The Section for Cellular Therapy has around 40 employees divided between a clinical Unit (GMP facility) and the Translational Research Unit (counting 18 employees) which is developing pre-clinical solutions in cancer immunotherapy. We have produced the first Norwegian CAR molecule - ananti-CD37CAR (Kksal Dillard et al. 2019 Caulier et al. 2024). Since then our collection has grown to almost 20 molecules prepared either from our own antibody stock or from home-made/self-produced antibodies. Our unit has the capacity to perform full pre-clinical validations of TCR and CAR molecules: Radium-1 TCR was also the first synthetic TCR ever tested in an academic clinical trial in Scandinavia (Radium-1 TCR NCT; Maggadottir et al. 2024). Furthermore our discoveries have led to the establishment of two biotech spin-offs: Ultimovacs and Zelluna AS now Zelluna ASA. We are located at the Oslo Cancer Cluster Incubator ( next to the Radium Hospital which represents anexcellent environment for innovative development.
Oslo University Hospital is a workplace with great diversity. We believe this is crucial for solving our tasks in the best possible way. We want this diversity to be reflected among the applicants for our positions and we encourage all qualified candidates regardless of background to apply!
The candidates must hold a PhD degree in Biology or Biochemistry. Other corresponding education in science (chemistry physics medicine pharmacy etc.) will be evaluated.
Knowledge and practical experience in all the following domains are mandatory and should be documented:
- Immune cell culture (PBMC isolation primary T-cell manipulation and functional assays)
- Immunological methods (flowcytometry ELISA)
- Animal experiment (FELASA-C or equivalent)
Experience in one or more of the following areas will be considered as an advantage:
- Molecular biology (cloning RNA isolation qPCR retro- or lentivirus manipulation)
- Cell biology: spheroid organoid culture or organ on a chip
- Protein expression and purification (bacteria or mammalian cells)
- Immunotherapy: vaccine development BiTE immune Receptor work (TCR CAR or others)
- Advanced microscopy (confocal) or live cell imaging
We are looking for a motivated hard-working and ambitious candidate who can independently plan and perform experiments write publications as well as applications and enjoys supervising students. Our team members work on different but related projects therefore the candidate will have to share and collaborate as well as participate in common responsibilities. We are a motivated open and ambitious team which offers a dynamic and modern and well-equipped environment as well as direct access to the hospital core facilities. Furthermore we support personal development and training in relevant areas.
Please respect the document length and do not use AI: exceeding document page number addition of unrequested documents and AI-generated documents will lead to disqualification.
Full-Time